Atrium Health Levine Cancer Institute | Strategic Alliance Partners

Latest from Atrium Health Levine Cancer Institute

Single-Agent and Combo Immunotherapy Garners Mixed Excitement in Gynecologic Cancers

September 30, 2021

Immunotherapy is emerging as a preferred second-line treatment option for patients with gynecologic cancers, including endometrial and cervical cancer. Checkpoint inhibitors may also be preferred to chemotherapy in the frontline or adjuvant settings based on improved efficacy.

GI Cancer Armamentarium Gains Traction With Immunotherapy, Targeted Agents

July 07, 2021

Jimmy Hwang, MD, discusses the frontline indications for checkpoint inhibitors in gastric cancer and their effect on subsequent treatment decisions, the growth of targeted therapy across gastrointestinal cancers, and expectations for future research and development.